accountProactive Investors USA & Canada Acadia surges on Parkinson's psychosis drug study San Jose Mercury News NEW YORK—Shares of Acadia Pharmaceuticals Inc. more than doubled to their highest price in more than three years Tuesday after the company said its drug pimavanserin reduced psychosis in patients with Parkinson's disease. Acadia said pimavanserin ... Acadia Reports Positive Results for...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Acadia surges on Parkinson's psychosis drug study - San Jose Mercury News
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account